Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease

Bibliography

• Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. Eye (Lond) 2007;21:604-8
   Google Scholar
• Richman J, Lorenzana LL, Lankaranian D, Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol 2010;17:144-51
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13. discussion 829-30
   PubMed Web of Science ®Google Scholar
• The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999;60:99-108
   PubMed Web of Science ®Google Scholar
• Lim LS, Mitchell P, Seddon JM, Age-related macular degeneration. Lancet 2012;379:1728-3
   PubMed Web of Science ®Google Scholar
• Kuno N, Fujii S. Dry age-related macular degeneration: recent progress of therapeutic approaches. Curr Mol Pharmacol 2011;4:196-232
   Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36
   PubMed Web of Science ®Google Scholar
• Shintani K, Shechtman DL, Gurwood AS. Review and update: current treatment trends for patients with retinitis pigmentosa. Optometry 2009;80:384-401
   PubMedGoogle Scholar
• Sahel J, Bonnel S, Mrejen S, Paques M. Retinitis pigmentosa and other dystrophies. Dev Ophthalmol 2010;47:160-7
   PubMedGoogle Scholar
• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795-809
   PubMed Web of Science ®Google Scholar
• Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000;118:264-9
   PubMed Web of Science ®Google Scholar
• Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ 1995;73:115-21
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Gordois A, Cutler H, Pezzullo L, An estimation of the worldwide economic and health burden of visual impairment. Glob Public Health 2012;7:465-81
   PubMed Web of Science ®Google Scholar
• Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004;82:887-8
   PubMed Web of Science ®Google Scholar
• Sommer A, Tielsch JM, Katz J, Racial differences in the cause-specific prevalence of blindness in east baltimore. N Engl J Med 1991;325:1412-17
   PubMed Web of Science ®Google Scholar
• Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician 2003;67:1937-44
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Cherry J, Lotery AJ. Age-related macular degeneration. Adv Exp Med Biol 2012;724:15-36
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S, The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc 2005;103:173-84. discussion 184-6
   PubMedGoogle Scholar
• Parmeggiani F. Clinics, epidemiology and genetics of retinitis pigmentosa. Curr Genomics 2011;12:236-7
   Google Scholar
• Frick KD, Roebuck MC, Feldstein JI, Health services utilization and cost of retinitis pigmentosa. Arch Ophthalmol 2012;130:629-34
   PubMedGoogle Scholar
• Sucampo acquires additional development and commercialization rights to unoprostone isopropyl in European Union and Switzerland from R-Tech Ueno [Internet]. Sucampo Pharmaceuticals, Inc., Bethesda, MD; 2011. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1541764&highlight= [Updated 3/22/11; Cited 24 May 2012]
   Google Scholar
• Rescula gets FDA approval as concomitant therapy. [Internet]. edition. Ocular Surgery News, U.S; 2000. Available from: http://www.healio.com/Ophthalmology/Glaucoma/news/print/Ocular-Surgery-News/%7B8614F751-7A5E-4F63-9D3F-46D3E381C8DC%7D/Rescula-gets-FDA-approval-as-concomitant-therapy?registered=1 [Cited 23 May 2012]
   Google Scholar
• Sucampo acquires rights to rescula for U.S. and Canada [Internet]. Sucampo Pharmaceuticals, Inc., Bethesda, MD; 2009. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1280130&highlight= [Updated 4/23/2009; Cited 23 May 2012]
   Google Scholar
• Sucampo Pharmaceuticals, Inc. reports first quarter 2012 financial and operating results [Internet]. Sucampo Pharmaceuticals, Inc., Bethesda, MD; 2012. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1694118&highlight= [Updated 05/09/12; Cited 26 May 2012]
   Google Scholar
• Sharif NA, Kelly CR, Crider JY, Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-15
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44:715-21
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther 2002;18:313-24
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J Ocul Pharmacol Ther 2008;24:152-63
   PubMedGoogle Scholar
• Bhattacherjee P, Paterson CA, Percicot C. Studies on receptor binding and signal transduction pathways of unoprostone isopropyl. J Ocul Pharmacol Ther 2001;17:433-41
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP, Cellular and molecular effects of unoprostone as a BK channel activator. Biochim Biophys Acta 2007;1768:1083-92
   PubMed Web of Science ®Google Scholar
• Sucampo Pharmaceuticals, Inc. reports second quarter and six months 2012 financial and operating results [Internet]. Sucampo Pharmaceuticals, Inc. Bethesda, MD; 2012. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1723412&highlight= [Cited 10 August 2012]
   Google Scholar
• Munemasa Y, Kitaoka Y, Hayashi Y, Effects of unoprostone on phosphorylated extracellular signal-regulated kinase expression in endothelin-1-induced retinal and optic nerve damage. Vis Neurosci 2008;25:197-208
   PubMedGoogle Scholar
• Melamed S. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma. Drugs Exp Clin Res 2002;28:63-7
   PubMedGoogle Scholar
• Hayami K, Unoki K. Photoreceptor protection against constant light-induced damage by isopropyl unoprostone, a prostaglandin F(2alpha) metabolite-related compound. Ophthalmic Res 2001;33:203-9
   PubMed Web of Science ®Google Scholar
• Mukuno H, Nakamura M, Kanamori A, Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr Eye Res 2004;29:457-64
   PubMed Web of Science ®Google Scholar
• Akiyama M, Ikeda Y, Yoshida N, In Neuroprotective efficacy of topical unoprostone isopropyl in patients with retinitis pigmentosa. ARVO annual meeting; 05/09/2012; Fort Lauderdale, FL; 2012
   Google Scholar
• Tsuruma K, Tanaka Y, Shimazawa M, Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels. Mol Vis 2011;17:3556-65
   PubMed Web of Science ®Google Scholar
• R-Tech Ueno discloses results of phase 2 retinitis pigmentosa clinical trial [Internet]. Sucampo Pharmaceuticals, Inc. Bethesda, MD; 2010. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1434785&highlight [Updated 05/04/2010; Cited 25 May 2012]
   Google Scholar
• Phase 2 clinical trial data of UF-021 in retinitis pigmentosa patients presented at ARVO 2011 [Internet]. Sucampo Pharmaceuticals, Inc. Bethesda, MD; 2012. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1559775&highlight= [updated 05/04/2011; Cited 26 May 2012]
   Google Scholar
• Yamamoto S, Sugawara T, Nakazawa M, Microperimetry shows protection of central vision in retinitis pigmentosa patients treated with UF-021: A phase 2 study. ARVO annual meeting; 05/04/2011; Fort Lauderdale, Fl; 2011
   Google Scholar
• Sugawara T, Yamamoto S, Nakazawa M, Humphrey perimetry 10-2 assessment of retinitis pigmentosa patients in phase 2 study of UF-021. ARVO annual meeting; 05/04/2011; Fort Lauderdale, FL; 2011
   Google Scholar
• A study to evaluate the ocular blood flow effects of unoprostone isopropyl in adults with dry age-related macular degeneration [Internet]: ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01379560?term=rescula&rank=1 [Updated 06/21/2011; Cited 20 May 2012]
   Google Scholar
• Product information; rescula, unoprostone isopropyl ophthalmic solution. Duluth, GA; 2001. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21214lbl.pdf
   Google Scholar
• German OL, Insua MF, Gentili C, Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem 2006;98:1507-20
   PubMed Web of Science ®Google Scholar
• Ueno R, Yoshida S, Deguchi T, The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals. Nihon Ganka Gakkai Zasshi 1992;96:462-8
   PubMedGoogle Scholar
• Taniguchi T, Haque MS, Sugiyama K, Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther 1996;12:489-98
   PubMed Web of Science ®Google Scholar
• Serle JB, Podos SM, Kitazawa Y, Wang RF. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998;42:95-100
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan G, Camras CB. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch Ophthalmol 2004;122:1782-7
   Google Scholar
• Thieme H, Stumpff F, Ottlecz A, Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2001;42:3193-201
   PubMed Web of Science ®Google Scholar
• Dismuke WM, Ellis DZ. Activation of the BK channel increases outflow facility and decreases trabecular meshwork cell volume. J Ocul Pharmacol Ther 2009;25:309-14
   Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP, Unoprostone isopropyl and metabolite M1 activate. BK channels and prevent ET-1-induced [Ca2+]i increases in human trabecular meshwork and smooth muscle. Invest Ophthalmol Vis Sci 2012;53:5178-89
   Google Scholar
• Kashiwagi K, Kanai N, Tsuchida T, Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism. Exp Eye Res 2002;74:41-9
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005;46:4159-63
   PubMed Web of Science ®Google Scholar
• Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci 2009;50:5259-65
   PubMed Web of Science ®Google Scholar
• Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11:112-15
   PubMedGoogle Scholar
• Sugiyama T, Mashima Y, Yoshioka Y, Effect of unoprostone on topographic and blood flow changes in the ischemic optic nerve head of rabbits. Arch Ophthalmol 2009;127:454-9
   Google Scholar
• Ohashi M, Mayama C, Ishii K, Araie M. Effects of topical travoprost and unoprostone on optic nerve head circulation in normal rabbits. Curr Eye Res 2007;32:743-9
   PubMed Web of Science ®Google Scholar
• Yu DY, Su EN, Cringle SJ, Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci 2001;42:1499-504
   PubMed Web of Science ®Google Scholar
• Kimura I, Shinoda K, Tanino T, Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients. Jpn J Ophthalmol 2005;49:287-93
   PubMedGoogle Scholar
• Tamaki Y, Araie M, Tomita K, Effect of topical unoprostone on circulation of human optic nerve head and retina. J Ocul Pharmacol Ther 2001;17:517-12
   PubMed Web of Science ®Google Scholar
• Makimoto Y, Sugiyama T, Kojima S, Azuma I. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the human ocular fundus. Jpn J Ophthalmol 2002;46:31-5
   PubMed Web of Science ®Google Scholar
• Polska E, Doelemeyer A, Luksch A, Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol 2002;120:348-52
   PubMedGoogle Scholar
• Yoshitomi T, Yamaji K, Ishikawa H, Ohnishi Y. Vasodilatory mechanism of unoprostone isopropyl on isolated rabbit ciliary artery. Curr Eye Res 2004;28:167-74
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol 2005;16:79-83
   PubMed Web of Science ®Google Scholar
• Polak K, Luksch A, Frank B, Regulation of human retinal blood flow by endothelin-1. Exp Eye Res 2003;76:633-40
   PubMedGoogle Scholar
• Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol 1995;39(Suppl 1):S49-56
   PubMed Web of Science ®Google Scholar
• Emre M, Orgul S, Haufschild T, Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol 2005;89:60-3
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim JY, Kim DM, Investigations on the association between normal tension glaucoma and single nucleotide polymorphisms of the endothelin-1 and endothelin receptor genes. Mol Vis 2006;12:1016-21
   Google Scholar
• Henry E, Newby DE, Webb DJ, Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest Ophthalmol Vis Sci 2006;47:2528-32
   PubMed Web of Science ®Google Scholar
• Haria M, Spencer CM. Unoprostone (isopropyl unoprostone). Drugs Aging 1996;9:213-18. discussion 219-20
   Google Scholar
• Yamamoto T, Kitazawa Y, Azuma I, Masuda K. Clinical evaluation of UF-021 (rescula; isopropyl unoprostone). Surv Ophthalmol 1997;41(Suppl 2):S99-103
   Google Scholar
• Azuma I, Masuda K, Kitazawa Y, Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-25
   PubMed Web of Science ®Google Scholar
• Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 1997;41(Suppl 2):S61-8
   Google Scholar
• Linden C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging 1999;14:387-98
   PubMed Web of Science ®Google Scholar
• Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res 1998;17:291-312
   PubMed Web of Science ®Google Scholar
• Susanna R Jr, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002;47(Suppl 1):S97-104
   Google Scholar
• Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf 2008;7:801-8
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Webers CA, Schouten JS, Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008;53(Suppl1):S69-84
   PubMedGoogle Scholar
• Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp Eye Res 2011;93:265-70
   PubMed Web of Science ®Google Scholar
• Ohashi M, Mayama C, Ishi K, Araie M. Local effect of topical FP-receptor agonists on retinal vessels of the ipsilateral posterior retina in normal rabbit eyes. Clin Experiment Ophthalmol 2008;36:767-74
   Google Scholar
• Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007;6:45-52
   PubMed Web of Science ®Google Scholar
• de Arruda Mello PA, Yannoulis NC, Haque RM. Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension. Drug Saf 2002;25:583-97
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma 2012;
   Web of Science ®Google Scholar
• Stewart WC, Kolker AE, Sharpe ED, Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000;130:274-9
   PubMed Web of Science ®Google Scholar
• Tezel G, Siegmund KD, Trinkaus K, Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol 2001;119:813-18
   Google Scholar
• Nakanishi Y, Nakamura M, Mukuno H, Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res 2006;83:1108-17
   PubMed Web of Science ®Google Scholar
• Drago F, Valzelli S, Emmi I, Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 2001;72:479-86
   PubMed Web of Science ®Google Scholar
• Kanamori A, Naka M, Fukuda M, Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res 2009;88:535-41
   PubMed Web of Science ®Google Scholar
• Emre S, Gul M, Ates B, Comparison of the protective effects of prostaglandin analogues in the ischemia and reperfusion model of rabbit eyes. Exp Anim 2009;58:505-13
   Google Scholar
• Akaishi T, Kurashima H, Odani-Kawabata N, Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J Ocul Pharmacol Ther 2010;26:181-6
   PubMedGoogle Scholar
• Kurashima H, Watabe H, Sato N, Effects of prostaglandin F(2alpha) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: Comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res 2010;91:853-9
   PubMed Web of Science ®Google Scholar
• Inan UU, Ermis SS, Orman A, The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther 2004;20:293-310
   PubMed Web of Science ®Google Scholar
• Koz OG, Ozsoy A, Yarangumeli A, Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand 2007;85:838-43
   PubMedGoogle Scholar
• Alagoz G, Gurel K, Bayer A, A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008;222:88-95
   Google Scholar